Abstract
Human papillomavirus (HPV) genotypes that infect the genital tract play a main etiologic role in cervical cancer progression. Other environmental factors, such as sexually transmitted diseases and the host genetic pattern, contribute to infection persistence of the uterus and cervical epithelium in sustaining their malignancy. The Janus kinase 2 is a non-receptor tyrosine kinase in cell signaling process of tumor genesis. In the present study, JAK2 V167F mutation was distinguished in women with sexually transmitted infections, such as Herpes simplex virus 2, Chlamydia trachomatis and Mycoplasma genitalium and cervical cancer. This case-control survey was performed on 195 liquid based cytology of women specimens. Fifty, 98, and 47 samples were from women with known cervical cancer, HPV positive and HPV negative, respectively. Single nucleotide polymorphism analysis, sexually transmitted infections detection and HPV genotyping were carried out using approved PCR- RFLP, in-house multiplex TaqMan Real Time PCR and the reverse dot blot hybridization assay. HPVs 6, 16, 18, 11, 31, and 51 were the most common genotypes. The prevalence rate of multiple HPV genotypes was 46.0% to 10.1%. Analysis of JAK2 V617F (1849 G > T) showed that pr...Continue Reading
References
Jul 20, 2007·Endocrine-related Cancer·Annika VaclavicekAsta Försti
Jul 25, 2009·International Journal of Cancer. Journal International Du Cancer·Marc ArbynPhilip E Castle
Apr 16, 2010·Journal of Molecular Medicine : Official Organ of the Gesellschaft Deutscher Naturforscher Und Ärzte·Geber PeñaLuis Ulloa
Jun 11, 2011·Pathology Research International·Osamu NunobikiSadamu Noda
Dec 2, 2011·Journal of Oncology·Sonya J Hwang, Kenneth R Shroyer
Dec 12, 2012·Pathology, Research and Practice·Nasrin ShayanfarAmir Sohrabi
Mar 1, 2013·Journal of Cellular and Molecular Medicine·Anca BotezatuGabriela Anton
Jan 22, 2014·Annals of Oncology : Official Journal of the European Society for Medical Oncology·M G DijkstraC J L M Meijer
Aug 16, 2014·Asian Pacific Journal of Cancer Prevention : APJCP·Amir SohrabiMarjan Rahnamaye-Farzami
Aug 17, 2014·Gynecologic Oncology·Zhengyan ZhangJanet S Rader
Aug 26, 2014·Oncogene·D ZhaoJ M Slingerland
Aug 30, 2014·Asian Pacific Journal of Cancer Prevention : APJCP·Amir SohrabiMohammad Hossein Modarresl
Apr 3, 2016·Annals of Global Health·R S Akram Husain, V Ramakrishnan
May 25, 2016·Clinical Laboratory·Amir SohrabiMonireh Babaei
Jan 22, 2017·International Journal of Cancer. Journal International Du Cancer·Srabani MittalRengaswamy Sankaranarayanan
Feb 22, 2017·Journal of Infection and Public Health·Amir SohrabiFaranak Kharazi
Mar 10, 2017·Expert Opinion on Investigational Drugs·Fabio BarraSimone Ferrero
Apr 7, 2017·Journal of Gynecologic Oncology·Dong Hoon SuhJae Weon Kim
Apr 14, 2017·Médecine et santé tropicales·R S Mboumba BouassaL Bélec
Apr 15, 2017·Human Vaccines & Immunotherapeutics·Nianmin ShiWenhui Gao
Apr 19, 2018·Medicine·Wei ZhangZhongqiu Xin
Jan 1, 2020·Infectious Disorders Drug Targets·Mona Moharreri, Amir Sohrabi
Citations
Apr 19, 2019·PloS One·Rafael Gutiérrez CamposAlejandro Rosas Cabral
Apr 18, 2019·Journal of Cancer Prevention·Stephen E Langabeer
Apr 18, 2019·Journal of Cancer Prevention·Amir Sohrabi
May 14, 2020·Journal of Cellular Physiology·Elham Golshekan, Amir Sohrabi
Nov 25, 2020·Journal of Molecular Neuroscience : MN·Nabanita RoyPankaj Barah
Jan 7, 2021·Journal of Obstetrics and Gynaecology of India·Amir SohrabiMohsen Imani
Jan 1, 2020·Infectious Disorders Drug Targets·Mona Moharreri, Amir Sohrabi